Polymeric Nanoparticles Containing Both Antigen and Vitamin D₃ Induce Antigen-Specific Immune Suppression

Ho-Hyun Jung, Sang-Hyun Kim, Jun-Hyeok Moon, Seong-Un Jeong, Sundong Jang, Chan-Su Park, Chong-Kil Lee

College of Pharmacy, Chungbuk National University, Cheongju 28644, Korea

ABSTRACT

The active form of vitamin D₃, 1,25-dihydroxyvitamin D₃ (aVD₃), is known to exert beneficial effects in the treatment of autoimmune diseases because of its immunosuppressive effects. However, clinical application of aVD₃ remains limited because of the potential side effects, particularly hypercalcemia. Encapsulation of aVD₃ within biodegradable nanoparticles (NPs) would enhance the delivery of aVD₃ to antigen presenting cells, while preventing the potential systemic side effects of aVD₃. In the present study, polymeric NPs containing ovalbumin (OVA) and aVD₃ (NP[OVA+aVD₃]) were prepared via the water-in-oil-in-water double emulsion solvent evaporation method, after which their immunomodulatory effects were examined. Bone marrow-derived immature dendritic cells (DCs) treated with NP(OVA+aVD₃) did not mature into immunogenic DCs but were converted into tolerogenic DCs, which express low levels of co-stimulatory molecules and MHC class II molecules, produce lower levels of pro-inflammatory cytokines while increasing the production of IL-10 and TGF-β, and induce the generation of Tregs. Intravenous injection with NP(OVA+aVD₃) markedly suppressed the generation of OVA-specific CTLs in mice. Furthermore, OVA-specific immune tolerance was induced in mice orally administered with NP(OVA+aVD₃). These results show that biodegradable NPs encapsulating both antigen and aVD₃ can effectively induce antigen-specific immune suppression.

Keywords: Polymeric nanoparticle; Vitamin D₃; Dendritic cells; Treg cells; Antigen-specific immune suppression

INTRODUCTION

The biologically active form of vitamin D₃, 1,25-dihydroxyvitamin D₃ (aVD₃), exerts various immunoregulatory and anti-inflammatory effects, in addition to the classical hormonal effects on calcium and phosphate metabolism (1,2). Numerous studies have shown that aVD₃ exerts immunomodulatory and anti-inflammatory effects primarily by modulating the function of dendritic cells (DCs) despite its direct immunosuppressive effects on T cells (3-6). DCs differentiated in the presence of aVD₃ exhibit the characteristics of tolerogenic DCs (1,2,7). DCs generated using aVD₃ express lower levels of MHC class II and co-stimulatory molecules and produce higher levels of IL-10 and lower levels of IL-12 and IL-6 compared to untreated normal
Conflicts of Interest
The authors declare no potential conflicts of interest.

Abbreviations
aVD₃, 1,25-dihydroxyvitamin D₃; DC, dendritic cell; i.v., intravenously; MLR, mixed lymphocyte reaction; NP, nanoparticle; NP[OVA+aVD₃], nanoparticles containing ovalbumin and 1,25-dihydroxyvitamin D₃; OVA, ovalbumin; PLGA, poly(D,L-lactide-co-glycolide)

Author Contributions
Conceptualization: Lee CK. Data curation: Jung HH, Kim SH. Formal analysis: Jung HH, Kim SH, Moon JH. Funding acquisition: Lee CK. Investigation: Jeong SU, Jang S. Methodology: Park CS. Supervision: Lee CK. Validation: Moon JH, Jeong SU, Jang S, Park CS. Writing - original draft: Jung HH. Writing - review & editing: Lee CK.

Polymeric nanoparticles (NPs) generated from a biodegradable and biocompatible polymer, poly(D,L-lactide-co-glycolide) (PLGA), have been extensively explored as implantable reservoirs for sustained-release drug delivery. PLGA NPs have also been studied as vehicles for the delivery of antigens to phagocytes (15-18). PLGA NPs containing both antigens and drugs have remarkable advantages because they can specifically deliver the antigens and the drugs to phagocytes, such as DCs and macrophages, thereby reducing the potential systemic side effects of the drugs (19,20).

Although the beneficial effects of aVD₃ are evident in many autoimmune disease models, numerous concerns have to be addressed before the clinical application of aVD₃ for the treatment of autoimmune diseases. One of the major concerns is the severe hypercalcemia, which could develop in patients receiving excessive amounts of aVD₃ (21,22). In the present study, PLGA NPs containing ovalbumin (OVA) and aVD₃ (NP[OVA+aVD₃]) were produced, with the goal of preferentially delivering OVA and aVD₃ to phagocytes. Our results confirmed that (NP[OVA+aVD₃]) could induce OVA-specific immune tolerance in mice that were intravenously injected or orally administered with the NPs.

MATERIALS AND METHODS

Animals
Female C57BL/6 and BALB/c mice (8 to 12 weeks old) were purchased from Kosa Bio Inc. (Seongnam, Korea). All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee (IACUC) of Chungbuk National University, Cheongju, South Korea and performed in accordance with the IACUC guidelines and regulations.

Generation of DCs from bone marrow cells
DCs were generated as previously described (15). Briefly, bone marrow cells obtained from mouse femurs were cultured in 6-well plates (5×10⁶ cells/well) containing culture medium supplemented with 40 ng/ml GM-CSF and 40 ng/ml IL-4 (both from CreaGene, Seongnam, Korea). After 3 days, the non-adherent cells were removed by gently shaking the plate and then replacing the medium. On day 4, the non-adherent cells were removed by the same method. On day 6, the DCs were harvested by gentle pipetting and used for the subsequent experiments.

Preparation of PLGA NPs
PLGA NPs containing OVA (Sigma-Aldrich, St. Louis, MO, USA) and aVD₃ (Sigma-Aldrich) were prepared following a previously described solvent evaporation method (23). Briefly, 600 μl of 80 mg/ml OVA in water was mixed by vortexing with 200 μl of 50% ethanol containing 400.0, 133.3, or 44.4 μg of aVD₃. The resulting mixture was mixed with 4 ml of 100 mg/ml PLGA (Evonik Industries, Essen, Germany) in ethyl acetate (Sigma-Aldrich) and then homogenized at 20,000 rpm (T10 basic Homogenizer, IKA, Staufen, Germany) for 3 min. The homogenate was added with 11 ml of a 5% polyvinyl alcohol aqueous solution (PVA, Sigma-Aldrich) and then homogenized at 20,000 rpm for 5 min. The double emulsion was added to 200 ml of a 0.1% PVA aqueous solution, and stirred at 500 rpm for 2 h to evaporate the organic solvent and solidify the NPs. The resulting NPs were centrifuged at 3,000 rpm for
20 min and washed twice with PBS. NPs containing only OVA (NP[OVA]) were prepared following the same method without adding aVD₃ to the PLGA solution. The NPs were prepared immediately before use, or frozen in aliquots at −20°C for later use.

**Characterization of PLGA NPs**
The mean size of the NPs was measured using a particle size analyzer (ELS-Z, Otsuka, Japan). The OVA content was determined using a microbicinchoninic acid assay kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions after lysing the NPs in a lysis buffer containing 0.1% SDS and 0.1 N NaOH. For aVD₃ quantitation, NPs were lysed in a 1:2 mixture of DMSO and methanol and then analyzed by HPLC analysis using a Waters HPLC system (Waters Corp., Milford, MA, USA) equipped with Waters 515 pumps, Waters 2996 photodiode array detector, and Waters Empower software using a YMC J’sphere ODS-H80 column (YMC America Inc., Allentown, PA, USA; 4 μm, 150×4.6 mm). Chromatographic separation was performed using a gradient solvent system of acetonitrile-water (ratio range, 20:80 to 100:0) for 30 min at a flow rate of 1.0 mL/min. aVD₃ concentrations were determined based on the ultraviolet absorbance at 240 nm.

**Phenotype analysis**
Cells were stained with monoclonal antibodies against mouse cell surface markers, CD11c, H-2Kb, I-Ab, CD80, CD86, CD4, CD25, Foxp3, and an isotype-matched control antibody (BD Biosciences, San Jose, CA, USA) as previously described (23). For intracellular Foxp3 staining, cells were permeabilized using the BD Cytofix/Cytoperm Plus kit (BD Biosciences) according to the manufacturer’s instructions. Subsequent analyses were performed using the FlowJo software (TreeStar, Ashland, OR, USA).

**Cytokine production analysis**
Immature DCs were harvested by gentle pipetting on day 6 and seeded in 24-well plates (1×10⁶ cells/well). Then, the immature DCs were treated with the indicated NPs (10 μg/ml as OVA) for 48 h. The amounts of TNF-α, IL-1β, IL-6, IL-12p40, and IL-10 in the culture supernatants were measured using commercial ELISA kits (BD Biosciences). TGF-β1 levels were measured using an ELISA kit from R&D systems (Minneapolis, MN, USA) after treating the culture supernatant with the Sample Activation Kit 1 (R&D systems) according to the manufacturer’s protocols.

**MHC class II-restricted OVA presentation assay**
DCs (1×10⁶ cells/well) were incubated with the indicated NPs (50 μg/ml as OVA) for 2 h, washed with pre-warmed PBS, fixed with 1% paraformaldehyde, and then washed with PBS. The OVA-specific CD4 T cell stimulatory capacity of the DCs was measured using OVA-specific CD4⁺ T cell hybridoma DOBW cells, which recognize OVA₃₂₃–₃₃₉-I-A² complexes and secrete IL-2 in response as previously described (23).

**Isolation of T cells**
Total T cells were purified from the spleens of BALB/c mice by adding the spleen cells to a nylon wool column and incubating for 1 h to remove adherent cells. CD4⁺CD25⁻ T cells were isolated from the adherent cell-depleted spleen cells of BALB/c mice using a CD4⁺CD25⁻ T cell isolation kit (Miltenyi Biotec Inc., Auburn, CA, USA).

**Allogeneic T cell stimulatory activity**
C57BL/6 bone marrow-derived DCs (1.25×10⁴, 2.5×10⁴, or 5×10⁴ cells/well) were treated with the indicated NPs (10 μg/ml as OVA) for 48 h, added with T cells (5×10⁵ cells/well) isolated
from the spleens of BALB/c mice, and subsequently cultured for 96 h. DNA synthesis was measured by incorporating (3H)-thymidine, which was added before the final 18 h of culture.

**Generation of Foxp3+ Tregs from naïve CD4+CD25− T cells**

DCs (2×10^4 cells/well) were treated with the indicated NPs (10 μg/ml as OVA) for 48 h and then co-cultured with purified CD4+CD25− T cells (2×10^5 cells/well) for 4 days in a medium containing 100 U/ml recombinant human IL-2 (PeproTech Inc., Rocky Hill, NJ, USA). The cells were stained with monoclonal antibodies specific to mouse CD4, CD25, and Foxp3, after which the proportion of CD25+Foxp3+ T cells in the CD4+ T cell population was determined by flow cytometry.

**In vivo OVA-specific CTL assay**

C57BL/6 mice were intravenously (i.v.) immunized with PBS, or the indicated NPs (100 μg/mouse as OVA). After 7 days, OVA-specific CTL activity was assessed using an in vivo CTL assay, as previously described (23). Briefly, splenocytes from naïve syngeneic mice were pulsed with 1 μM OVA_{257-264} peptide for 1 h at 37°C and then labeled with a high concentration of CFSE (25 μM). The other control target population was syngeneic splenocytes labeled with a low concentration of CFSE (5 μM) without pulsing with the OVA peptide. A 1:1 mixture of each target cell population was injected via the tail vein into the immunized mice (1×10^7 cells/mouse). After 18 h, specific killing of OVA peptide-pulsed target cells was determined using spleen cells isolated from each mouse by flow cytometry.

**OVA-specific IgG measurement**

C57BL/6 mice were i.v. immunized with PBS or the indicated NPs (100 μg/mouse as OVA). After 7 days, sera were collected, and the amounts of OVA-specific IgG were measured by an ELISA. Briefly, 96-well immunoplates were coated overnight with OVA (2 mg/ml in PBS), blocked with 10% FBS in PBS, and loaded with 1:20,000 dilutions of serum. After 2 h of incubation, the plates were washed and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG antibodies (Sigma-Aldrich; 1:5,000) to allow specific binding, followed by washing and incubation with 3,30,5,50-tetramethylbenzidine (BD Biosciences) substrate solution and 1 M H_2SO_4 stop solution. The absorbance was measured at the wavelengths of 450 and 570 nm using an ELISA plate reader.

**Induction and assessment of OVA-specific oral tolerance**

C57BL/6 mice was intragastrically administered with PBS or the indicated NPs (200 μg/mouse as OVA) on days 0 and 2. On day 9, mice were i.v. immunized with NP(OVA) (80 μg/mouse as OVA). OVA-specific CTL activity and OVA-specific IgG production were assessed at 7 days after i.v. immunization with NP(OVA) as described above.

**Statistical analysis**

One-way ANOVA analysis and Tukey post-hoc tests were performed to compare the significance of multiple groups. p≤0.05 was considered statistically significant.

**RESULTS**

**Fabrication and characterization of NPs containing OVA and aVD_3**

NP(OVA) and NP(OVA+ aVD_3) were fabricated with PLGA using the water-in-oil-in-water double emulsion solvent evaporation method. The OVA and aVD_3 ratios (w/w) used to generate 3 types of NPs containing OVA plus aVD_3 were 200:1, 600:1, and 1800:1,
and the resultant NPs were designated as NP(200:1), NP(600:1), and NP(1,800:1). The physicochemical properties of the NPs were evaluated (Table 1). The mean diameters of the NP(OVA), NP(200:1), NP(600:1), and NP(1,800:1) were 724.1±98.4, 786.1±76.8, 838.4±94.3, and 800.8±82.4 nm, respectively. The average aVD₃ contents in NP(200:1), NP(600:1), and NP(1,800:1) were 7.5, 2.8, and 0.08 μg/mg OVA. Thus, the average OVA: aVD₃ ratios (w/w) in the NP(200:1), NP(600:1), and NP(1,800:1) were 133:1, 357:1, and 1,250:1, respectively.

### Table 1. Characterization of PLGA-NPs

<table>
<thead>
<tr>
<th>Nanoparticles</th>
<th>Size (nm)</th>
<th>OVA loading efficiency (%)</th>
<th>aVD₃ loaded (µg/mg OVA)</th>
<th>OVA: aVD₃ ratio in the NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>NP(OVA)</td>
<td>724.8±98.4</td>
<td>10.8±0.7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NP(200:1)</td>
<td>786.1±76.8</td>
<td>12.9±0.8</td>
<td>7.5±0.06</td>
<td>133:1</td>
</tr>
<tr>
<td>NP(600:1)</td>
<td>838.4±94.3</td>
<td>13.8±0.7</td>
<td>2.8±0.02</td>
<td>357:1</td>
</tr>
<tr>
<td>NP(1,800:1)</td>
<td>800.8±82.4</td>
<td>13.3±0.6</td>
<td>0.8±0.01</td>
<td>1,250:1</td>
</tr>
</tbody>
</table>

DCs phagocytosed of NP(OVA+aVD₃) exert properties of tolerogenic DCs

To examine the effects of NP(OVA+aVD₃) on the maturation and function of DCs, immature DCs generated from mouse bone marrow cells were treated with NP(OVA+aVD₃) for 2 days. Phenotypic analysis of the DCs showed that NP(OVA+aVD₃)-treated DCs expressed considerably lower levels of MHC class II (I-A<sup>b</sup>, CD80, and CD86 molecules, and the inhibitory effects of NP(OVA+aVD₃) were dose-dependent on the concentrations of aVD₃ in the NPs (Fig. 1).

Phagocytosis of NPs by itself activates DC maturation and cytokine production. As shown in Fig. 2, DCs treated with NP(OVA) produced large amounts of pro-inflammatory cytokines, such as IL-1β, TNF-α, IL-12, and IL-6. The production of these inflammatory cytokines was significantly suppressed in NP(OVA+aVD₃)-treated DCs, and the inhibitory effects were dependent on the amounts of aVD₃ in the NPs (Fig. 2). By contrast, NP(OVA+aVD₃)-treated DCs produced significantly higher amounts of IL-10 and TGF-β compared to DCs treated with NP(OVA), and these enhancing effects were also found to be dependent on the amounts of aVD₃ in the NPs.

The capacity of NP-treated DCs to stimulate T cells was additionally investigated by performing MHC class II-restricted exogenous antigen presentation assay and allogeneic
mixed lymphocyte reaction (MLR). In exogenous antigen presentation assays, DCs were incubated with the NPs for 2 h, washed, fixed, and then co-cultured with OVA-specific CD4^+ T cell hybridoma, DOBW cells, which recognize OVA\textsubscript{323−339}-I-A\textsuperscript{d} complexes and secrete IL-2 (23).

The MHC class II-restricted OVA peptide presentation capacity of NP(OVA+aVD\textsubscript{3})-treated DCs was significantly lower compared to that of NP(OVA)-treated DCs, and the observed inhibitory effects were dependent on the amounts of aVD\textsubscript{3} in the NPs (Fig. 3A). In addition, allogeneic T cell stimulation by NP(OVA+aVD\textsubscript{3})-treated DCs was significantly weaker.

Figure 2. Effects of NP(OVA+aVD\textsubscript{3}) on cytokine production in DCs. Immature DCs generated from bone marrow cells of C57BL/6 mice were treated with NP(OVA), NP(1,800:1), NP(600:1), or NP(200:1) (10 µg/ml as OVA) for 48 h. Cytokine secretion in the culture supernatant was determined by ELISA. Data are presented as the mean±SD of 3 independent experiments.

*p<0.05.

Figure 3. DCs treated with NP(OVA+aVD\textsubscript{3}) are impaired in both MHC class II-restricted exogenous antigen presentation and allogeneic T cell stimulatory capacity. (A) Immature DCs generated from bone marrow cells of BALB/c mice were treated with NP(OVA), NP(1,800:1), NP(600:1), or NP(200:1) (50 µg/ml as OVA) for 2 h. After washing and fixing, DCs were co-cultured with OVA\textsubscript{323−339}-specific DOBW cells. The supernatants were harvested, and IL-2 production was measured by ELISA. Data are presented as the mean±SD of 3 independent experiments. (B) Immature DCs generated from C57BL/6 mouse bone marrow cells were treated with NP(OVA), NP(1,800:1), NP(600:1), or NP(200:1) (10 µg/ml as OVA) for 48 h. DCs were then co-cultured with T cells isolated from the spleens of BALB/c mice at the indicated ratios for 96 h. T cell proliferation was measured by the incorporation of \textsuperscript{(3)}H-thymidine added during the final 18 h of culture.

**p<0.01.
compared to that by NP(OVA)-treated DCs, and the degree of suppression was found to be dependent on the amounts of aVD₃ in the NPs (Fig. 3B).

**NP(OVA-aVD₃)-treated DCs induce Foxp3⁺ Tregs**
The ability of NP(OVA+aVD₃)-treated DCs to induce the conversion of naïve CD4⁺ CD25⁻ T cells into Foxp3⁺ Tregs was evaluated *in vitro*. To analyze the ability of NP(OVA+aVD₃)-treated DCs to induce Tregs, immature DCs generated from C57BL/6 mouse bone marrow cells were treated with NP(OVA) or NP(OVA+aVD₃) for 48 h. DCs were then co-cultured with CD4⁺CD25⁻ T cells isolated from the spleens of BALB/c mice in the presence of recombinant human IL-2 (100 U/ml) for 4 days, after which CD25 and Foxp3 expression levels in the T cells were determined (Fig. 4A). The proportions of CD25⁺Foxp3⁺ Tregs were significantly higher in co-cultures with NP(1,800:1)-treated DCs (7.7%), NP(600:1)-treated DCs (8.9%), or NP(200:1)-treated DCs (10.0%), than those of co-cultures with NP(OVA)-treated DCs (3.24%) (Fig. 4B).

**Mice injected with NP(OVA-aVD₃) show suppressed OVA-specific CTL responses**
In this experiment, mice were i.v. injected with PBS, NP(OVA), or NP(200:1). After 7 days, OVA-specific CTL activity was assessed using CFSE-labeled syngeneic target cells. Representative histograms are shown in Fig. 5A. Mice that were injected with NP(OVA) showed potent OVA-specific CTL responses (specific killing, 82.8%). However, mice that injected with NP(200:1) showed significantly suppressed OVA-specific CTL responses (specific killing, 24.2%; Fig. 5B).

**Oral administration of mice with NP(OVA-aVD₃) induces OVA-specific immune tolerance**
To investigate whether OVA-specific oral tolerance could be induced by oral administration of NP(OVA+aVD₃), mice were intragastrically injected with PBS, NP(OVA), or NP(200:1) on days 0 and 2. On day 9, mice were i.v. immunized with PBS or NP(OVA). After 7 days, OVA-specific CTL activity was assessed using CFSE-labeled syngeneic target cells. Representative histograms are shown in Fig. 6A. Oral administration of mice with NP(OVA) did not induce...
Figure 5. Effect of i.v. treatment of NP(OVA+aVD$_3$) on OVA-specific CTL generation in vivo. (A) PBS, NP(OVA), or NP(200:1) (100 µg/mouse as OVA) was i.v. injected into C57BL/6 mice. After 7 days, OVA-specific cytotoxic activity was assessed by an in vivo CTL assay. The target cells were a 1:1 mixture of syngeneic cells pulsed with the OVA$_{257-264}$ peptide and then labeled with a high concentration of CFSE and syngeneic cells non-pulsed and labeled with a low concentration of CFSE. The target cells were i.v. injected into recipient mice, and the specific cytotoxicity was evaluated after 18 h. The number of mice in each group was 5. (B) The proportion of killed target cells in each experimental group is shown. Data are presented as the mean±SD of 3 independent experiments.

Figure 6. Effect of oral treatment of NP(OVA-aVD$_3$) on OVA-specific responses in vivo. (A) Induction of OVA-specific CTLs. PBS, NP(OVA), or NP(200:1) (200 µg/mouse as OVA) was i.v. injected into C57BL/6 mice on days 0 and 2. On day 7, mice were i.v. injected with NP(OVA) (80 µg/mouse as OVA). After 7 days, OVA-specific cytotoxic activity was assessed using an in vivo CTL assay, as shown in Fig. 5. The number of mice in each group was 5. (B) The proportion of killed target cells in each experimental group is shown. Data are presented as the mean±SD of 3 independent experiments. (C) Production of OVA-specific IgG. PBS, NP(OVA), or NP(200:1) (200 µg/mouse as OVA) was intragastrically injected into C57BL/6 mice on days 0 and 2. On day 7, sera were collected from the mice, and OVA-specific IgG levels were measured by ELISA. Data are presented as the mean±SD of 3 independent experiments.

**p<0.01.
OVA-specific T cell tolerance, as evidenced by the similar rate of target cell killing in PBS-administered mice following i.v. re-challenge with NP(OVA). However, oral administration of mice with NP(200:1) significantly induced OVA-specific T cell tolerance, as evidenced by the significantly reduced rate of target cell killing compared to NP(OVA)-administered mice following i.v. re-challenge with NP(OVA) (Fig. 6A and 6B). OVA-specific IgG production was also examined using sera collected from the mice described in Fig. 6A. The level of OVA-specific IgG in the serum was evidently lower in mice orally administered with NP(200:1) compared to that in NP(OVA)-administered mice (Fig. 6C).

DISCUSSION

Induction of Ag-specific immune suppression or tolerance is one of the ultimate goals in the immunotherapy of autoimmune diseases and other harmful immunological reactions. In the present study, we showed that i.v. injection of biodegradable polymeric NPs containing antigen and the active form of aVD₃ is a useful method for inducing antigen-specific immune suppression in mice. In addition, our results showed that oral feeding of biodegradable polymeric NPs containing antigen and aVD₃ could also induce antigen-specific immune suppression in mice.

The 2 primary main sources of vitamin D₃ are dietary uptake and synthesis in the skin (7,24). In the human skin, vitamin D₃ is synthesized from 7-dihydroxycholesterol when exposed to ultraviolet B. In the liver, vitamin D₃ is hydroxylated to 25-hydroxyvitamin D, which is the main circulating form of vitamin D₃. 25-hydroxyvitamin D₃ is further hydroxylated further into aVD₃ by the kidney enzymes to exert its biological activity (7,25).

The active form of vitamin D₃ has long been established to play an important role in the innate and adaptive immune responses (26-29). Low serum concentrations of aVD₃ have been associated with higher rates of infections and the development of autoimmune diseases, such as multiple sclerosis, type 1 diabetes mellitus, and systemic lupus erythematosus (30-33). aVD₃ exerts immunomodulatory activities both directly by activating T cells and indirectly via modification of antigen-presenting cell. aVD₃ inhibits the secretion of proinflammatory cytokines from Th1, Th9, Th17, and Th22 cells, but promotes Th2 production of cytokines, such as IL-4, IL-5, and IL10, thereby skewing T cells towards Th2 polarization (3-6,33). In addition, aVD₃ in combination with IL-2 promotes the development of Tregs expressing CTLA-4 and FoxP₃ (3). Moreover, numerous studies have shown that aVD₃ primarily exerts its immunomodulatory and anti-inflammatory effects by modulating the function of DCs. Both in vivo and in vitro experiments have demonstrated that DCs differentiated in the presence of aVD₃ exhibit the properties of tolerogenic DCs characterized by downregulated CD40, CD80, and CD86 expression, low IL-12 production, and enhanced IL-10 secretion (2,7-10). Moreover, these DCs act as poor activators of antigen-primed T cells but stimulate the generation of Tregs, which play critical roles in the antigen-specific immune suppression (10-14,34). The above findings showed that aVD₃ exerts beneficial effects on the immune function, particularly in the context of autoimmunity, via generation of tolerogenic DCs.

The clinical application of aVD₃ is limited by its potential side effects, particularly hypercalcemia (35). In fact, the conversion of the circulating, inactive form of vitamin D₃ to its active form (aVD₃) is strictly regulated by the parathyroid hormone and the phosphaturic hormone fibroblast growth factor 23 (7). In this regard, encapsulation of aVD₃ with a
biodegradable polymer would not only reduce the potential systemic side effects of aVD$_3$, but also preferentially target the delivery of aVD$_3$ to phagocytes, such as macrophages and DCs. Our results showed that NP(OVA+aVD$_3$)-treated DCs showed impaired antigen-specific T cell stimulation, expression of MHC class II and co-stimulatory molecules (CD80 and CD86), and secretion of pro-inflammatory cytokines (IL-1β, IL-6, IL-12, and TNF-α). However, the production of the immunosuppressive cytokine IL-10 was increased in NP(OVA+aVD$_3$)-treated DCs. Furthermore, NP(OVA+aVD$_3$)-treated DCs induced Foxp3$^+$ Tregs from naïve CD4 T cells. These results demonstrated that the DCs treated with NP(OVA+aVD$_3$) are converted into tolerogenic DCs.

Notably, our findings showed that NP(OVA+aVD$_3$) can induce OVA-specific immune tolerance in mice orally administered or i.v. injected with the NPs. Mice i.v. injected with NP(OVA+aVD$_3$) showed suppressed induction of OVA-specific cytotoxic T cells. In addition, mice that were orally administered with NP(OVA+aVD$_3$) exhibited markedly impaired generation of OVA-specific cytotoxic T cells and OVA-specific IgG upon i.v. re-challenge with NP(OVA). These results demonstrated that NP(OVA+aVD$_3$) can induce OVA-specific oral tolerance.

In summary, the present study showed that DCs treated with NP(OVA+aVD$_3$) exhibit tolerogenic DC properties. Tolerogenic DCs generated by NP(OVA+aVD$_3$) efficiently induced the differentiation of naïve T cells into regulatory T cells. Our findings also demonstrate that oral administration or intravenous injection of NP(OVA+aVD$_3$) enhanced OVA-specific immune suppression in mice. Therefore, polymeric NPs encapsulating both antigen and aVD$_3$ can be used to effectively induce antigen-specific immune tolerance, which is crucial for the treatment of autoimmune diseases.

ACKNOWLEDGEMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2017R1A2B4006828, MRC-2017R1A5A2015541).

REFERENCES


